Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Avexis Inc (AVXS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,111,014
  • Shares Outstanding, K 31,980
  • Annual Sales, $ 0 K
  • Annual Income, $ -83,010 K
  • 36-Month Beta 3.00
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.80

Price Performance

See More
Period Period Low Period High Performance
1-Month
90.73 +7.22%
on 11/13/17
108.27 -10.15%
on 11/02/17
-3.94 (-3.89%)
since 10/17/17
3-Month
85.77 +13.42%
on 09/12/17
108.27 -10.15%
on 11/02/17
+5.71 (+6.24%)
since 08/17/17
52-Week
44.68 +117.73%
on 12/14/16
108.27 -10.15%
on 11/02/17
+29.28 (+43.06%)
since 11/17/16

Most Recent Stories

More News
AveXis Reports Third Quarter 2017 Financial and Operating Results

- First patient has been dosed in pivotal trial of AVXS-101 for SMA Type 1 -

AVXS : 97.28 (-1.50%)
Biotech Stocks on Investors' Radar -- Aralez Pharma, Arena Pharma, Arrowhead Pharma, and AveXis

If you want a Stock Review on ARLZ, ARNA, ARWR, or AVXS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Tuesday, November 07, 2017, US markets saw...

ARLZ : 1.65 (unch)
ARWR : 3.70 (+3.06%)
ARNA : 26.53 (-0.08%)
AVXS : 97.28 (-1.50%)
AveXis to Report Third Quarter 2017 Financial and Operating Results

AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will report financial and operating...

AVXS : 97.28 (-1.50%)
AveXis Announces New England Journal of Medicine Publication of Phase 1 Data of AVXS-101 Gene Replacement Therapy in Spinal Muscular Atrophy Type 1

--- As of August 7, 2017, all patients are alive, event-free and have reached at least 20 months of age -

AVXS : 97.28 (-1.50%)
G-CON Manufacturing Announces Completion and Delivery of G-CON PODs(R) to AveXis for AveXis' State of the Art Gene Therapy Facility

G-CON today announced the completion and delivery of a G-CON POD(R) system to AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...

AVXS : 97.28 (-1.50%)
AveXis to Report Top-line Data from the Phase 1 Clinical Trial of AVXS-101 in SMA Type 1 at the International Annual Congress of the World Muscle Society

- All patients were alive and event-free at 20 months of age as of the August 7, 2017 data cut-off -

AVXS : 97.28 (-1.50%)
Featured Company News - AveXis Intends To Initiate Pivotal Trial Of AVXS-101 In SMA Type 1 On An Immediate Basis

LONDON, UK / ACCESSWIRE / October 3, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for AveXis, Inc. (NASDAQ: AVXS), following which we have published...

AVXS : 97.28 (-1.50%)
AveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 Using Product from New GMP Commercial Process

- FDA notified AveXis it may initiate pivotal trial based on a review of data provided by the company following CMC Type B meeting -

AVXS : 97.28 (-1.50%)
AveXis Reports Second Quarter 2017 Financial and Operating Results

- AveXis on track to submit potency assay data to FDA in August -

AVXS : 97.28 (-1.50%)
AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

AveXis, Inc. (NASDAQ:AVXS) today announced the closing of its previously announced underwritten public offering of 4,111,250 shares of its common stock at a price to the public of $70.00 per share before...

AVXS : 97.28 (-1.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant...

See More

Key Turning Points

2nd Resistance Point 100.09
1st Resistance Point 98.69
Last Price 97.28
1st Support Level 95.78
2nd Support Level 94.27

See More

52-Week High 108.27
Last Price 97.28
Fibonacci 61.8% 83.98
Fibonacci 50% 76.47
Fibonacci 38.2% 68.97
52-Week Low 44.68

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart